

# INDEX

- Acetylcholine
  - in Alzheimer's disease, 1, 5–7
  - neurons, 4
  - in Parkinson's disease, 1
  - receptors, 4, 8, 65, 75, 207–209
    - density, 5
    - junction, 6
    - membrane, 6
    - subtypes
      - muscarinic, 4
      - nicotinic, 66–73
        - conformation states
          - resting state, 67
          - putative activated, 68
          - putative desensitized, 68, 69
  - subtypes
    - muscarinic, 4, 5
    - nicotinic, 6, 7
  - synthesis, 4, 6
- Acetylcholinesterase, 4
  - in Alzheimer's disease, 5
  - anticholinesterase agents, 5, 6, 65
  - release, 5
  - inhibitors
    - action
      - effect on cognition, 51
      - effect on cfos gene expression, 51
- Activity monitor, 32
- Acupuncture, 2, 109
- Adenylate cyclase, 7
- Alzheimer's disease, 1
  - diagnostic scales
    - DSMIII, Reisburg Global Determination Scale, 57
    - NINCDS-ADRDA Critiria, 57
  - etiology, 4, 6
  - pathology, 6
    - hisopathological changes, 6, 57, 58
  - Neurochemical changes, 1, 4–6, 47, 48, 57
    - cholinergic hypothesis of memory dsyfunc-tion, 5
  - beta amyloid plague, 58
- Alzheimer's disease
  - therapy strategies
    - basic research
      - chemicals investigated for efficacies
        - brain gangliosides, 59–61
        - genetic risk, 6
        - MAO inhibitors on cognitive behavior, 15
        - neuron rescue, 16, 18
        - neurotransmitters release, 48
        - putative drugs tests on monkey, 5
      - surgical invasive reseach in animals
        - embryonic septo-hippocampus graft
    - clinical
      - correct neurochemical dysfunctions
        - anticholinesterase, 5, 47
        - muscarinic receptor agonists, 5
        - precursor therapy (choline), 5, 47
        - muscarinic agonists, 5, 47
- Amantidine, 3, 25
- Aminoethyl-chloro-benzamide, 25
- Aminoethyl-chloropyridine, 25
- Amitriptyline, 79
- AMPA, 123–128
- Amphatamine, 17–19
- Angiotensin II, 5
- Apolipoprotein E (APOE), 6
- Apomorphine, 3, 25
- APP, 6
- Arecoline, 5
- Arginine, 3
- Asiogliosides, 57, 60, 61
- Baclofen progabide, 3, 191
- Behavioral tests on learning and memory, 50
- Blood brain barrier, 2, 19
- Botulinum A, 6
- Brain-derived neurotrophic factor, 4
- Brain ischemia
  - animal model, 133
  - study on occlusion time and neurotransmitters, 139–141

- Brain ischemia (*cont.*)  
 symptoms, 124  
   antioxidant enzyme activities, 141  
   delay neuronal death, 124  
   electrical activity arrest, 124  
   glutamate release, 125  
   loss of consciousness, 124  
   monoamine and metabolites levels changed,  
     133–136  
   transmitters release, 125  
 types, 124  
   focal, 133  
   global, 133
- Bromocriptine, 3, 25
- Budipine, 25
- Carbidopa, 3
- Cerebral palsy  
 clinical symptom, 183  
 CT scan, 183  
 treatment  
   Chinese herbs, 183
- Cerebrovascular disease  
 cerebral hemorrhage, 158  
 cerebral ischemic lesion, 158, 187  
 cerebral infarction, 161, 162  
   with myocardial, 162  
 epidemiological survey, 156  
 prevalence rate, 157–159  
 risk factors, 160
- Cereplasmin, 198, 204
- Chinese traditional medicine, 6, 27, 28, 143, 169, 184
- Choline, 5, 47
- Chromosome, 6, 21
- Clomipramine, 78
- Clonazepam, 3
- Copper in cytosol of fibroblasts  
 concentration, 199  
 distribution, 200
- Cobalt, 168
- Corydalis, 27
- Curare, 6, 66
- Cyclic adenine, 3'5' monophosphate cAMP, 7, 143,  
 151
- Cyclic guanine, 3'5' monophosphate cGMP, 7, 151
- Dementia, 14, 53
- Depression  
 clinical assessment  
   Clinical Global Impression Chart (CGI), 112–  
     119  
   Grading Scale, 112  
   Rating Scale of Side Effects (ASBERG), 112–  
     119  
 diagnostic criteria  
   Criteria at Huangshan China Symposium, 1981  
     110  
   Hamilton Depressive Rating Scales, 110
- Depression (*cont.*)  
 diagnostic criteria (*cont.*)  
   Handbook of Epidemiologic Survey of Mental  
     Disease in China, 110  
   Present State Examination, 110  
   WHO Standardized Assessment of Depression,  
     110
- types  
 depressive psychosis, 112  
 manic depression, 112  
 neurosis, 112  
 schizophrenia, 79, 112  
 treatment  
   acetazolamide, 191  
   adenosine, 193  
   amoxapine, 191  
   carbamazepine, 190  
   chlorpromazine, 191  
   citalopram, 194  
   clomipramine, 78, 194  
   haloperidol, 191  
   lithium, 189  
   mechanism, 194  
   thyroid hormone, 191  
   valproate, 190  
     antimanic, 190, 191
- Depressive disorders  
 basic research  
   development of putative drugs  
     serotonin reuptake inhibitors, 79, 80, 84  
     serotonin inhibitors efficacies, 89  
     interaction of chemicals with neurotransmit-  
       ter receptors, 88
- clinical  
 classification  
   unipolar  
     asthenic, 189  
   bipolar  
     genetic penetrant, 189  
     syntonic, 189
- therapy  
 chemicals  
   mood stabilizer, 191  
     mechanism, 191–193  
   norepinephrine uptake inhibitors in neuron,  
     78  
   serotonin inhibitors, 78  
   tryptophan, 79  
   5HTP + MAO, 79
- others  
 acupuncture, 109  
   changes in neurochemicals, 79, 120  
   computer control electro-acupuncture,  
     110  
   electro-acupuncture, 109
- Desimipramine (DMI), 28, 31, 78
- Dexetimide, 25
- Diabetes mellitus, 160

- Dopa  
 D,L-dopa, 3  
 L-dopa, 3, 4, 18, 25  
 Dopac, 18, 21, 134, 135, 137  
 Dopamine, 30, 133, 134  
 in neurons, 27, 30  
 in Parkinson's disease, 1  
 in Psychopharmacological study and psychiatric patients, 1, 2  
 levels in brain, 1, 21, 25, 29, 31, 194  
 receptors  
 D<sub>1</sub>, 27, 28  
 D<sub>2</sub>, 27, 28  
 release, 48  
 structure, 2  
 uptake in brain, 21, 77, 79  
 DSP-4 18, 21
- Eaton-Lambert Syndrome, 208  
 Epidermal growth factor (EGF), 4  
 Electron probe x-ray microanalysis (EPXMA), 168  
 Epilepsy, 193  
 animal model  
 pentylenetetrazol-induced, 165  
 cobalt focus epilepsy model, 174  
 basic research  
 techniques  
 astrocytes culture, 172  
 patch clamp, 170  
 primary neuron culture, 170  
 symptoms  
 bursting activity in cerebral cortex, 165, 168  
 change in intracellular calcium, 168  
 seizure activity, 168  
 transmembrane ion movement, 168  
 therapy  
 herbal mixture, 168  
 effect on intractable epilepsy, 169  
 inhibit convulsion, 169  
 normalized  
 calcium incorporate to protein, 170  
 calcium shift, 170  
 protein level, 170  
 seizure-related cellular phenomena, 170  
 protect neuron damage, 170  
 phenytoin PHT, 172–176  
 valproic acid, 175
- Fluoxetine (prozac), 82, 83  
 functions, 86, 87  
 pharmacological responses, 88  
 Fura, 2 168
- Galanin, 4  
 Gama amino-butyric acid (GABA), 3, 137, 138, 191  
 Ganglioside  
 assay, 58  
 content, 59, 61, 172
- Ganglioside (*cont.*)  
 synthesis, 57, 58  
 GM1 ganglioside, 4  
 Glutamate, 125  
 excitatory hypothesis, 125  
 effects on  
 cellular calcium influx, 125  
 plasma glucose level, 125  
 temperature  
 revive excito toxic, 126  
 L-glutamic acid, 123  
 G-protein, 6, 123  
 Graphic computer (3-D), 8  
 Growth hormone, 4  
 Guanylate cyclase, 7, 27
- 5HIAA, 18, 21, 134, 136, 137  
 Homovanilic acid (HVA), 18, 21, 134, 135, 137  
 Huatuo reconstruction pill (HTRP), 183  
 actions  
 determining techniques, 184  
 effects on  
 blood supply to ischemia focus, 187  
 carotid blood flow, 184, 185  
 heart performance, 187  
 histamine, 185  
 myocardial contractility, 186  
 6-hydroxydopamine (6-OHDA), 25, 27, 28  
 5-hydroxytryptamine, 5HT (serotonin), 3, 18, 31,  
 77, 97, 133–137, 194  
 receptor subtypes, 97–105  
 antagonists, 97  
 binding assay, 98  
 intra-species heterogeneity, 105  
 intra-tissue heterogeneity, 105
- Hypertension, 160
- Ilexonin A  
 source - Chinese herb, 143  
 therapy for cerebrovascular disease, 143  
 actions  
 affect action potential of muscle cell, 147  
 beta-receptor blocker, 151  
 effects on Hiss bundle electrograph, 143, 146  
 influence  
 arterial blood pressure, 145, 150  
 calcium flux, 148, 149  
 carotid sinus reflex, 145  
 cyclic AMP, 148, 150  
 myocardial contractility, 144
- Ion channels, 6, 97, 125  
 calcium, 1, 2, 53, 123, 125, 148  
 potassium, 52, 125, 170  
 sodium, 2, 7, 8
- Isoprenaline, 151
- Lanthanum, 168  
 Lecithin, 5

- Linopiridine  
   actions on  
     cerebral glucose metabolism, 51  
     cerebral cortical electroencephalographic, 51  
     cfos gene expression, 51  
     cognitive behavior, 50  
     transmitters release, 48, 49  
   mechanism, 52, 53  
   pharmacological activity, 53  
 Lisuride, 3, 25  
  
 Metal toxin, 6  
 Metallothionein, 198, 200, 203, 204  
 Methylene blue dye, 32  
 Milacemide, 19  
 Molecular receptor modeling, 8  
   electro interaction, 8  
   steric interaction, 8  
 Monoamine oxidase (MAO) inhibitors, 3, 15, 19  
   function, 3  
   in Alzheimer's disease, 15–18  
   in depression, 17  
   in Parkinson's disease, 3, 15–18, 25  
   sub-types  
     MAO-A, 20  
     MAO-B  
       deamination, 15, 19  
       neurochemical effects, 15, 16, 21  
       neuroprotective effects, 15, 16, 21  
       with amphetamine moiety, 15–17  
       with aliphatic amines, 17–21  
       analogues, 19–22  
 MPP<sup>+</sup> 15, 18, 19, 29–44  
   actions  
     on behavior, 37, 38  
     on dopamine nerve terminal, 30  
     on free radicals, 30  
     on monoamine, 37  
   <sup>3</sup>H dopamine uptake, 39, 41  
   <sup>3</sup>H NE uptake, 40, 42  
   <sup>3</sup>H 5HT uptake, 41, 42  
 MPTP, 3, 15, 18, 19, 21, 22, 29–44  
   metabolites (DMI,NOH)  
     on behavior, 35  
     on monoamine, 35  
     on NE neurons, 30  
     on tremor frequency, 38  
 Myasthenia Gravis, 6, 207  
   alpha-bungarotoxin, 209  
   beta-bungarotoxin, 207–209  
   antibody, 207  
   cGMP content in brain, 7  
   neurological change, 208  
 Myelin, 208  
  
 NBQX  
   block synaptic transmission, 126  
 Neostigmine, 151  
  
 Neurotoxin, 6, 7, 30, 207  
 Neurotransmitters  
   imbalance, 3–6  
   interaction with receptors, 88  
   structures, 2  
   uptakes, 77  
 Nicotinamide adenine dinucleotide (NADH), 25  
 Nicotine, 3, 6  
 Nifedipine, 149, 151  
 NMDA, 52, 123, 125  
 Nomifensin, 29, 31  
 Nortriptyline, 79  
 Norepinephrine (NE), 2, 18, 21, 29–31, 77, 78, 133, 148  
  
 Parkinson's disease  
   basic research  
     animal models for Parkinson's disease  
       reserpine treated, 1  
       MPTP model, 3, 15, 18, 21, 29  
       effect on behavior, 37, 38  
       effects on monoamines, 37  
       effects on tremor frequency, 3  
       MPTP metabolites, 15, 18, 21, 29–44  
       neurotoxicity, 30  
     perspective therapeutic strategies  
       antioxidants, 4  
       Chinese herbs extract, 27, 28  
       fetal and adrenal transplants with MRI, 4  
       gama-aminobutyric acid, 3  
       glutamate inhibitors, 3  
       GM1 ganglioside, 4  
       growth factors, 4  
       novel dopamine agonists, 4, 21, 27  
       neuroleptics, 4,  
   clinical  
     symptoms, 30  
     side effects after treatment, 3, 18, 25  
   treatment  
     chemicals  
       anticholinergic agents, 3, 25  
       COMT inhibitors, 3, 25  
       decarboxylase + l-dopa, 2, 3, 25  
       dopaminergic agonists, 2, 3, 25  
       dopamine release enhancers, 3  
       dopamine synthesis stimulants, 3  
       MAO inhibitors, 3, 15, 18, 25  
       melanocytes stimulating hormone antagonist, 25  
     surgery  
       adrenal medulla autografts, 4  
       fetal substantia transplantation, 4  
       stereotactic surgery, 4  
 Pentyenetetrazol, 168–176  
 Pergoline, 3, 25  
 Phenoxyphenyl propylamine  
   structure-activity relationship, 82  
 Phentolamine, 149

- Phosphotidylcholine, 47
- Physostigmine, 5, 47
- Piracetam, 5
- PLG (MIF), 25
- Propranolol, 151
- Potassium, 1, 52
  
- Reserpine, 1, 27, 78, 191
  
- Selegiline (L-deprenyl)
  - Actions
    - on dopamine neurotransmission, 15
    - on MAO inhibition, 15, 18, 19
    - on production of toxic oxidative radical, 15, 19
    - trophic-like, 15
- Signal transduction, 8
- Sinemet, 3, 25
- Sodium nitrite, 185
- Somatostatin, 5
- Synaptosome, 32
  
- Tetrabiopterine, 25
- Tetracyclic, 109
- Tetrahydroaminoacridine, 47
- Tetrahydroprotoberberines (THPBs), 27
- Thioridazine, 7
- ThreoDOPs, 25
  
- Toxins
  - alpha-bungarotoxin, 6, 65, 75, 207, 209
  - alpha-cobrotoxin, 66, 75
  - beta-bungarotoxin, 207–209
  - Kappa-bungarotoxin, 75, 76
    - action, 76
    - binding site, 76
  - organophosphates, 65
    - types
      - phencyclidine, 65
      - sarin, 65
      - soman, 65
      - tabun, 65
- Tremor monitor, 32
- Tricyclic, 3, 78, 109, 189
- Tyrosine hydroxylase, 30
- Trihexyphenidyl, 25
  
- Wilson disease, 197
  - clinical diagnosis, 198, 204
    - biochemical examination, 198
    - copper/protein ratio, 199, 204
    - skin fibroblast culture, 198, 204
  - copper metabolism, 198
  - in vitro model, 203
  - pathological symptom, 198
  - prevalence, 198